{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"10.0","upperLimit":"17.0","value":"14.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"52"}],"units":"Participants"}],"description":"overall survival was measured from time of initiation of treatment to death from any cause","dispersionType":"95% Confidence Interval","groups":[{"description":"cisplatin 75 mg/m2, pemetrexed 500 mg/m2 and bevacizumab 15 mg/kg IV every 3 weeks","id":"OG000","title":"Cisplatin, Pemetrexed and Bevacizumab"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up 100 months","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"months"}